Osmotica Pharmaceuticals plc Reports Second Quarter 2019 Results
August 08, 2019 16:05 ET
|
Osmotica Holdings US LLC
Second quarter 2019 total revenue of $57.5 million On track to submit NDA for RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for acquired blepharoptosis, or droopy eyelid, by...
Osmotica Pharmaceuticals plc to Provide Second Quarter 2019 Business and Financial Update on August 8, 2019
August 01, 2019 16:30 ET
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the...
Osmotica Pharmaceuticals plc to Present at Jefferies 2019 Global Healthcare Conference
May 30, 2019 16:30 ET
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., May 30, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that...
Osmotica Pharmaceuticals plc to Present at 2019 RBC Capital Markets Global Healthcare Conference
May 14, 2019 16:30 ET
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., May 14, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that...
Osmotica Pharmaceuticals plc Reports First Quarter 2019 Financial Results and Highlights Pipeline and Business Progress
May 09, 2019 16:01 ET
|
Osmotica Holdings US LLC
First quarter 2019 total revenue of $57.1 million; net loss of $6.2 million Positive topline results from second Phase III clinical trials of RVL-1201 for ptosis or droopy eyelid BRIDGEWATER, N.J.,...
Osmotica Pharmaceuticals plc Announces Positive Topline Results of Phase III Clinical Trials of RVL-1201 (“RVL”) for Acquired Blepharoptosis (ptosis or droopy eyelid)
May 06, 2019 16:30 ET
|
Osmotica Holdings US LLC
- Second Phase III Study 202 Meets Primary Endpoint; Provides Additional Evidence of Efficacy and Safety - - Long-term Phase III Study 203 Provides Additional Evidence of Safety - - Company to Host...
Osmotica Pharmaceuticals plc to Provide First Quarter 2019 Business and Financial Update on May 9, 2019
May 02, 2019 17:00 ET
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the...
Osmotica Pharmaceuticals plc Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress
March 27, 2019 16:05 ET
|
Osmotica Holdings US LLC
Reported fourth quarter and full year 2018 total revenue of $65.7 million and $263.7 million, respectively Completed and reported preliminary topline results from second Phase III study of arbaclofen...
Osmotica Pharmaceuticals plc to Provide Fourth Quarter and Full Year 2018 Business and Financial Update on March 27, 2019
March 21, 2019 18:02 ET
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., March 21, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that...
Osmotica Pharmaceuticals Appoints Seasoned Financial Executive Gregory Cowan to Board of Directors and Audit Committee
December 27, 2018 07:00 ET
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Dec. 27, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that...